Abeona Therapeutics Stock News

NEW YORK and CLEVELAND, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that information about the comp

NEW YORK and CLEVELAND, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that information about the companys ABO-102 pivotal Transpher A study in Sanfilippo syndrome type A (MPS IIIA) will be presented at the 14 th International Congress of Inborn Errors of Metabolism (ICIEM). The meeting will take place virtually and at the Hilton Sydney in Sydney, Australia on November 21-23, 2021.

Catalyst Biosciences, Inc. (CBIO) with the stream of -2.40% also noticed, India Abeona Therapeutics Inc. (ABEO) encountered a rapid change of -1.77% in the last hour of Tuesdays trading session. The post Bright Stock Buzz: Catalyst Biosciences, Inc. (NASDAQ:CBIO), Abeona Therapeutics Inc. (NASDAQ:ABEO) appeared first on Stocks Equity .

Abeona Therapeutics (NASDAQ:ABEO) posted its quarterly earnings data on Sunday. The biopharmaceutical company reported ($0.16) EPS for the quarter, hitting the consensus estimate of ($0.16), Fidelity Earnings reports. Abeona Therapeutics stock traded down $0.02 during mid-day trading on Tuesday, hitting $0.89. The stock had a trading volume of 201 shares, compared to its average volume […]

Abeona Therapeutics (NASDAQ:ABEO) released its quarterly earnings results on Sunday. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, hitting the Zacks consensus estimate of ($0.16), Fidelity Earnings reports. Shares of NASDAQ:ABEO opened at $0.91 on Tuesday. The company has a market cap of $92.18 million, a P/E ratio of -1.57 and a []

NEW YORK and CLEVELAND, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Vish Seshadri, Ph.D., Chie

Phase 3 VIITAL study on track to complete enrollment in first quarter 2022 with final patients identified and under screening

Full and original release on www.actusnews.com . Subscribe to this company''s information.

NEW YORK and CLEVELAND, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Vish Seshadri, Ph.D., M.B.A.

NEW YORK and CLEVELAND, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced two presentations of previously d

NEW YORK and CLEVELAND, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Jon Voss as Vi

Steven H. Rouhandeh to retire as Chairman of the Board; Michael Amoroso appointed Chairman of the Board

NEW YORK and CLEVELAND, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that members of the company's ma